Navigation Links
Selexis to Exhibit at BIO Taiwan 2013
Date:7/16/2013

Geneva, Switzerland (PRWEB) July 16, 2013

Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today that representatives from the Company will be participating in the BIO Taiwan 2013 conference being held July 18 - 21, 2013 at Taipei Word Trade Center – Nangang Exhibition Hall in Nangang, Taipei, Taiwan.

Selexis has partnerships and commercial deals with leading biotechnology and pharmaceutical companies worldwide. The Selexis SUREtechnology Platform™ offers a range of solutions for recombinant protein expression and protein therapeutic development, including technologies and expression libraries for overcoming a wide range of secretion bottlenecks, screening platforms to facilitate lead identification of clinical candidates and development of high producing clonal cell lines for therapeutic protein programs. Selexis’ SUREtechnology Platform™ can be applied from early drug discovery to cGMP manufacturing, resulting in faster, more reliable, higher-expressing mammalian cell lines that can be applied to a wide range of areas such as diagnostics, drug discovery, therapeutics and bio-manufacturing.

Representatives will be available to discuss Selexis’ capabilities. Companies or individuals attending BIO Taiwan 2013 can meet with Selexis representatives at the BioAlps Lake Geneva Life Science Cluster booth number I216-218.
For more information, please visit http://www.bioclub.com.tw/en/vis_info.asp

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis generated cell lines are being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information:

Read the full story at http://www.prweb.com/releases/selexis_bio_taiwan/cell_line_development/prweb10927923.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Selexis SA to Present at Biotech Showcase 2012
2. Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development
3. Data on the Selexis SUREtechnology Platform to be Presented at PEPTALK 2013
4. Selexis SA to Present at Cell Line Development and Engineering 2013
5. Selexis SA to Speak on Next Generation Innovations for Secretion Bottlenecks at the 2013 Protein Engineering Summit (PEGS)
6. At RSNA, DR Systems Will Exhibit RIS, Reporting, Peer Review Systems
7. 2011 ErgoExpo Attendees Choice Award Winners Announced During Sold Out Expo; Exhibitor Renewal for 2012 Hits 96% and Counting
8. FirstMark to Exhibit at Cardiovascular Research Technologies (CRT) 2012 Conference
9. FirstMark Exhibiting at the American College of Cardiology 61st Annual Scientific Sessions & Expo
10. NanoLogix Announces Development of Multi-Well, Rapid Diagnostic Test Variant and Exhibits at the American Society for Microbiology General Meeting in San Francisco
11. The Human Genome Is Displayed in the Dimension of Time in Web-Based Exhibition by Yonder Biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Benchworks ... 22 in Philadelphia. The event was offered by the Chamber of Commerce for ... featured breakout groups and interaction with speakers who are leaders in their industries. ...
(Date:3/28/2017)... , Belgium , March 28, 2017 ... VolitionRx Limited (NYSE MKT: VNRX), today announced the engagement of ... DVD Associates, LLC, as a strategic consultant. Dr. Vollmer ... identifying and securing non-dilutive funding in the State ... United States . Dr. Vollmer Dahlke has ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... initial release of LabKey’s newest software solution, LabKey Biologics . Built in ... pharma and biotech organizations, LabKey Biologics provides drug research teams tools for biological ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... development of a new orally administered treatment for Alzheimer’s disease (AD), today announced ... Didsbury states, “As we seek to uniquely treat the metabolic dysfunctions inherent in ...
Breaking Biology Technology:
(Date:3/7/2017)... , March 7, 2017   HireVue , the ... global companies identify the best talent, faster, today announced ... Sales Officer (CSO) and Diana Kucer as ... out a seasoned executive team poised to drive continued growth ... on a year of record bookings in 2017. ...
(Date:3/2/2017)... 2, 2017 Australian stem cell and regenerative ... has signed an agreement with the Monash Lung Biology ... Discovery Institute and Department of Pharmacology at Monash University, ... preclinical study to support the use of Cymerus™ mesenchymal ... Asthma is a chronic, long term lung ...
(Date:2/27/2017)... WASHINGTON , Feb. 27, 2017   Strategic ... fund, today announced it has led a $3.5 million investment ... collaboration platform. Strategic Cyber Ventures is DC based and ... and Hank Thomas . Ron Gula , ... Tech Ventures, also participated in this series A round ...
Breaking Biology News(10 mins):